The biomanufacturing legacy of the Grifols campus in Emeryville, California, began with Chiron and Cetus in the 1980s, with innovative advancements in yeast expression, viral discovery and the development of PCR. Three decades of process development and manufacturing experience is the foundation of the business today at Grifols Recombinant Protein Contract Development and Manufacturing Organization (CDMO).
Recently, Grifols expanded its focus to apply its expertise to producing therapeutic proteins for biopharmaceutical organizations. Its new GMP consolidated manufacturing facility (CMF) supports this expansion. The CMF facility houses multiproduct production and features state-of-the-art equipment, including a distributed control system and a central data historian. We sat down with seven diverse experts at Grifols Recombinant Protein CDMO to discuss how the group’s legacy and recent investments support its future in providing recombinant protein CDMO services.